PFM Health Sciences’s Akero Therapeutics AKRO Stock Holding History

PFM Health Sciences’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-248,079	Closed	-$11.8M	–	79
2025 Q3	$11.8M	Sell	248,079 -18,088	-7%	-$876K	0.91%	37
2025 Q2	$14.2M	Buy	+266,167	New	+$12.1M	1.21%	27
2023 Q4	–	Sell	-214,298	Closed	-$10.8M	–	64
2023 Q3	$10.8M	Buy	+214,298	New	+$9.98M	0.51%	52

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PFM Health Sciences's AKRO Position: Q4 2025 in Review

PFM Health Sciences sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 248,079 shares — an estimated $11.8M sold.

PFM Health Sciences first reported a position in AKRO in Q3 2023 and held it in 3 quarters. The position peaked at $14.2M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

PFM Health Sciences reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
PFM Health Sciences sold 248,079 Akero Therapeutics shares in Q4 2025, an estimated $11.8M.
PFM Health Sciences first reported a position in Akero Therapeutics in Q3 2023 and held it in 3 quarters.
PFM Health Sciences's Akero Therapeutics position peaked at $14.2M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on PFM Health Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.